VIVUS (NASDAQ:VVUS) was downgraded by analysts at Piper Jaffray from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.comreports. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.89 moved to $5.97 on last trade day and at the end of the day closed at $5.80. Company price to sales ratio in past twelve months was calculated as 7.39 and price to cash ratio as 1.75. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -2.52 %.
EXACT Sciences Corporation (NASDAQ:EXAS)’s shares dropped 5.68% to $13.44. The company on Apr. 2 announced that it is offering $125 million of shares of its common stock in a proposed underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. EXACT Sciences Corporation (NASDAQ:EXAS) shares fell -9.33% in last trading session and ended the day on $12.92. EXAS return on equity ratio is recorded as -35.60% and its return on assets is -33.00%. EXACT Sciences Corporation (NASDAQ:EXAS) yearly performance is 29.20%.
Horizon Pharma (NASDAQ:HZNP) had its price objective hosited by Stifel Nicolaus from $18.00 to $25.00 in a report released on Friday, Stock Ratings Network.com reports. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -8.39% in last trading session and was closed at $14.85 while trading in range of $14.58 – $16.41 – Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 94.88%.
Venaxis, Inc. (NASDAQ:APPY) intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Venaxis Inc (NASDAQ:APPY) weekly performance is -8.40%. On last trading day company shares ended up $2.29. Venaxis Inc (NASDAQ:APPY) distance from 50-day simple moving average (SMA50) is -12.28%. Analysts mean target price for the company is $5.67.